A Comparison of Mometasone to Advair in Patients With Milder Persistent Asthma

Summary

The research hypothesis for the proposed study asks the question, can Asmanex® demonstrate comparable anti-inflammatory therapeutic efficacy to the combination product, Advair® in control of mild persistent asthma? The purpose is to demonstrate that the anti-inflammatory protection afforded by monotherapy with an inhaled steroid (Asmanex®) is comparable to combination therapy with Advair® 100/50, when measured by this standard methodology (methacholine bronchoprovocation) in subjects with mild persistent asthma.

Timeline

Start

2007-04

Primary completion

2010-01-19

Completion

2010-01-19

Outcome

Outcome not reported

Stopped (Enrollment): “by sponsor due to failure to recruit patients who had mild persistent asthma who were not already on Advair 250/50 or 500/50.”

Drugs

Indications